Neoadjuvant therapy for locally advanced melanoma: New strategies with targeted therapies

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 1115-1121

  La Greca, Michele ^a   Grasso, Giuseppe ^a   Antonelli, Giovanna ^a   Russo, Alessia Erika ^a   Bartolotta, Salvatore ^b   D'Angelo, Alessandro ^a   Vitale, Felice Vito ^a   Ferraù, Francesco ^a  

^a San Vincenzo Hospital   (Italy)

^b Surgical Unit Casa di Cura Gretter Lucina   (Italy)

Author keywords

Advanced melanoma; Biologic; Neoadjuvant setting; Targeted therapy; Vemurafenib

Indexed keywords

CISPLATIN; DACARBAZINE; FENTANYL; FLUORODEOXYGLUCOSE; PARACETAMOL; VEMURAFENIB; VINDESINE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CUTANEOUS MELANOMA; DRUG TOLERABILITY; HUMAN; INGUINAL ADENOPATHY; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MALE; PELVIC ADENOPATHY; PELVIC PAIN; POSITRON EMISSION TOMOGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84902961140     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/ott.s62699     Document Type: Article

References (19)

1. Tarhini AA, Pahuja S, Kirkwood JM. Neoadjuvant therapy for high-risk bulky regional melanoma. J Surg Oncol. 2011;104(4):386-390.
2. Davar D, Tarhini AA, Kirkwood JM. Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach. Clin Dermatol. 2013;31(3):237-250.
3. Sarnaik AA, Zager JS, Sondak VK. Multidisciplinary management of special melanoma situations: oligometastatic disease and bulky nodal sites. Curr Oncol Rep. 2007;9(5):417-427.
4. Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol. 2006;24(19): 3164-3171.
5. Lewis KD, Robinson WA, McCarter M, et al. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol. 2006;24(19):3157-3163.
6. Buzaid AC, Colome M, Bedikian A, et al. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res. 1998;8(6):549-556.
7. Atkins MB, Hsu J, Lee S, et al; Eastern Cooperative Oncology Group. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008;26(35):5748-5754.
8. Keilholz U, Punt CJ, Gore M, et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2005;23(27):6747-6755.
9. Sasson HN, Poo WJ, Bakas MH, Ariyan S. Prolonged survival in patients with advanced melanoma treated with neoadjuvant chemotherapy followed by resection. Ann Plast Surg. 1996;37(3):286-292.
10. Kounalakis N, Gao D, Gonzalez R, et al. A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes. Immunotherapy. 2012;4(7):679-686.
11. Jouary T, Legros C, Lalanne N, et al. Neoadjuvant chemotherapy: a new criterion for selection of candidate patients for surgery of low tumour burden metastases from malignant melanoma? Br J Dermatol. 2010;163(1):183-187.
12. Shah GD, Socci ND, Gold JS, et al. Phase II trial of neoadjuvant temozolomide in resectable melanoma patients. Ann Oncol. 2010;21(8): 1718-1722.
13. Janco JM, Markovic SN, Weaver AL, Cliby WA. Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy. Gynecol Oncol. 2013;129(3): 533-537.
14. Mozzillo N, Caracò C, Mori S, et al. Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma. J Transl Med. 2012;10:131.
15. Foote M, Burmeister B, Dwyer P, et al. An innovative approach for locally advanced stage III cutaneous melanoma: radiotherapy, followed by nodal dissection. Melanoma Res. 2012;22(3):257-262.
16. Tarhini AA, Edington H, Butterfield LH, et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014;9(2):e87705.
17. Kolar GR, Miller-Thomas MM, Schmidt RE, Simpson JR, Rich KM, Linette GP. Neoadjuvant treatment of a solitary melanoma brain metastasis with vemurafenib. J Clin Oncol. 2013;31(3):e40-e43.
18. Koers K, Francken AB, Haanen JB, Woerdeman LA, van der Hage JA. Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma. J Clin Oncol. 2013;31(16):e251-e253.
19. Fadaki N, Cardona-Huerta S, Martineau L, et al. Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib. BMJ Case Rep. 2012;2012.